Binds Plasma Protein, Serum Protein, Or Fibrin (e.g., Clotting Factor, Fibrinolytic Factor, Complement Factor, Immunoglobulin, Apolipoprotein, Etc.) Patents (Class 530/388.25)
  • Patent number: 9766234
    Abstract: The invention relates to a screening process for determining a disordered von Willebrand factor (VWF)-GPIb interaction in a patient's sample. This comprises contacting the sample with isolated GPIb.alpha. protein, with VWF protein and with a solid phase associated with an antibody specific for said isolated GPIb.alpha. protein, and determining complex formation.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: September 19, 2017
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventor: Juergen Patzke
  • Patent number: 9585956
    Abstract: The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: March 7, 2017
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Patent number: 9156887
    Abstract: Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: October 13, 2015
    Assignee: Janssen Biotech, Inc.
    Inventor: Steven Jacobs
  • Patent number: 9150638
    Abstract: The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: October 6, 2015
    Assignee: Justus-Liebig-Universität Giessen
    Inventors: Ewa Jablonska, Klaus Preissner, Malgorzata Wygrecka
  • Patent number: 9028801
    Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: May 12, 2015
    Assignees: Electrophoretics Limited, Medical Research Council, University College London
    Inventors: Malcolm Andrew Ward, John Collinge, Graham Stuart Jackson, Emma McGregor, Nicola Louise Leeds, James Campbell, Jules Arthur Westbrook, Helen Louise Byers
  • Patent number: 9028816
    Abstract: The present invention relates to polypeptides and polypeptide constructs comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation.
    Type: Grant
    Filed: January 9, 2004
    Date of Patent: May 12, 2015
    Assignee: Ablynx N.V.
    Inventor: Karen Silence
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Patent number: 9012609
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: April 21, 2015
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Haren Arulanantham, Thil Dinuk Batuwangala, Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
  • Patent number: 9012154
    Abstract: The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement ac
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: April 21, 2015
    Assignees: Rigshospitalet, University of Copenhagen
    Inventors: Peter Garred, Christian Honore
  • Patent number: 9000134
    Abstract: The invention provides reagents and methods for diagnosing kidney disease in a human or animal.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: April 7, 2015
    Inventors: Wallace B. Haigh, Donald L. Very, Jr.
  • Patent number: 8999339
    Abstract: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: April 7, 2015
    Inventor: Clifford G. Risk
  • Publication number: 20150093395
    Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 2, 2015
    Applicants: VANDERBILT UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Andras Gruber, Erik I. Tucker, David Gailani
  • Patent number: 8980836
    Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: March 17, 2015
    Assignee: The Regents of the University of California
    Inventor: Katerina Akassoglou
  • Patent number: 8969024
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 3, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Patent number: 8957187
    Abstract: The invention provides antibodies or antigen binding fragments thereof to DR5 and HER-2. The antibodies and/or antigen binding fragments thereof comprise variant CDRs comprising highly restricted amino acid sequence diversity. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as at least a portion of phage or viral coat proteins, tags and linkers. In addition, compositions and methods of use for treatment of cancer and immune related conditions are provided.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: February 17, 2015
    Assignee: Genentech, Inc.
    Inventors: Sachdev S. Sidhu, Sara C. Birtalan, Frederic A. Fellouse
  • Patent number: 8940883
    Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: January 27, 2015
    Assignees: Oregon Health & Science University, Vanderbilt University
    Inventors: Andras Gruber, Erik I. Tucker, David Gailani
  • Patent number: 8927220
    Abstract: A protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. A diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein are provided. The degree of the progression of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). The monoclonal antibody is used in early diagnosis and progression detection of IgA nephropathy and development of a novel drug for the purpose of treatment.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: January 6, 2015
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Moon Chang Baek, Pyong Gon Moon, Yong Lim Kim
  • Patent number: 8901282
    Abstract: The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: December 2, 2014
    Assignee: Rappaport Family Institute for Research in the Medical Sciences
    Inventors: Jacob Victor, Noah Berkowitz, Andrew Levy
  • Publication number: 20140349323
    Abstract: The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay.
    Type: Application
    Filed: August 5, 2014
    Publication date: November 27, 2014
    Inventors: Ulrich Essig, Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
  • Patent number: 8877195
    Abstract: The present invention provides an isolated antibody that binds a fibrin or fibrinogen ?C domain. In various aspects, the antibody inhibits microglial adhesion to the fibrin or fibrinogen ?C domain, inhibits Mac-1 binding to the fibrin or fibrinogen ?C domain, and/or suppresses clinical symptoms of Experimental Autoimmune Encephalomyelitis (EAE). Various methods of using the antibodies, pharmaceutical compositions, kits, vectors, cells comprising the vectors, and antibody generating methods are provided.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: November 4, 2014
    Assignee: The Regents of the University of California
    Inventor: Katerina Akassoglou
  • Patent number: 8877197
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: November 4, 2014
    Assignee: True North Therapeutics, Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Patent number: 8865425
    Abstract: The present invention relates to a reagent for the measurement of FDP comprising a carrier sensitized with at least two monoclonal antibodies selected from three monoclonal antibodies having different reactivity towards FDP. The present invention also relates to a reagent kit comprising the reagent and a method for measurement of FDP using the reagent or reagent kit.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: October 21, 2014
    Assignee: Sysmex Corporation
    Inventors: Katsushi Kobayashi, Masumi Murakami, Mayumi Sugimoto
  • Patent number: 8865424
    Abstract: The present invention relates to an anti-FDP monoclonal antibody selected from the first, second and third monoclonal antibodies having different reactivity towards FDP. The present invention also relates to a reagent and reagent kit for the measurement of FDP and a method for measurement of FDP using the anti-FDP monoclonal antibodies.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: October 21, 2014
    Assignee: Sysmex Corporation
    Inventors: Naoya Okitsu, Katsushi Kobayashi, Noriaki Nakajima, Masumi Murakami, Kouji Sakaguchi, Ayumi Asaeda, Mayumi Sugimoto
  • Patent number: 8846869
    Abstract: Provided is a mutant protein capable of binding specifically and quickly to troponin I derived from human myocardium. The mutant protein comprises a first mutant scFv antibody fragment 51 a second mutant scFv antibody fragment 52 and a linker 53. The first mutant scFv antibody fragment 51 comprises a first light chain variable region 51L consisting of an amino acid sequence represented by SEQ ID NO: 76 and a first heavy chain variable region 51H consisting of an amino acid sequence represented by SEQ ID NO: 77. Similarly, the second mutant scFv antibody fragment 52 comprises amino acid sequences of SEQ ID NO: 78 and SEQ ID NO: 79. The linker 53 is provided between the C-terminus of the first heavy chain variable region 51H and the C-terminus of the second heavy chain variable region 52H.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: September 30, 2014
    Assignee: Panasonic Corporation
    Inventor: Takashi Endoh
  • Publication number: 20140271660
    Abstract: This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin ? complexed with heparin and/or heparin-like structure (AT?H). These AT?H binding proteins can block the anti-coagulant activity of AT? to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: BAYER HEALTHCARE LLC
    Inventors: YE JIN, JOHN E. MURPHY, TERRY HERMISTON, TIMOTHY MYLES, FRANK DITTMER, MICHAEL STRERATH, UWE GRITZAN
  • Patent number: 8828395
    Abstract: Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: September 9, 2014
    Assignee: aTyr Pharma, Inc.
    Inventors: Jeffry Dean Watkins, Alain P. Vasserot, Rajesh Belani, Leslie Ann Greene, Ryan Andrew Adams
  • Patent number: 8828676
    Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: September 9, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • Patent number: 8809508
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: August 19, 2014
    Assignee: Probiodrug AG
    Inventors: Martin Kleinschmidt, Stephan Schilling, Jens-Ulrich Rahfeld, Kristin Ebermann, Hans-Ulrich Demuth
  • Patent number: 8802096
    Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
    Type: Grant
    Filed: November 26, 2010
    Date of Patent: August 12, 2014
    Assignee: Inflarx GmbH
    Inventors: Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen
  • Publication number: 20140220042
    Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.
    Type: Application
    Filed: April 16, 2014
    Publication date: August 7, 2014
    Applicant: Academia Sinica
    Inventors: Tse Wen Chang, Jiun-Bo Chen, Pheidias C. Wu, Alfur F. Hung
  • Patent number: 8795664
    Abstract: The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated A? starting with pyroglutamate (A??E), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing A? oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: August 5, 2014
    Assignees: Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin, Synaptic Systems Gesellschaft für Neurobiologische Forschung, Entwicklung und Produktion mbH
    Inventors: Thomas Bayer, Oliver Wirths, Henrik Martens, Christian Erck
  • Publication number: 20140212433
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 31, 2014
    Applicant: Genentech, Inc.
    Inventors: ARTHUR HUANG, ROBERT KELLEY, HENRY LOWMAN, MENNO VAN LOOKEREN CAMPAGNE, CHARLES WINTER
  • Patent number: 8791243
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: July 29, 2014
    Assignee: Onclave Therapeutics Limited
    Inventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall, Jose Saldanha
  • Publication number: 20140199361
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: July 20, 2012
    Publication date: July 17, 2014
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Patent number: 8779103
    Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: July 15, 2014
    Assignee: Glaxo Group Limited
    Inventors: Christopher Herring, Lucy J. Holt, Laurent S. Jespers, Sebastian Mayer, Malgorzata Pupecka-Swider
  • Patent number: 8765131
    Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: July 1, 2014
    Assignee: Genentech, Inc.
    Inventors: Michael Fung, William N. C. Sun, Cecily R. Y. Sun
  • Publication number: 20140154705
    Abstract: A method is described for obtaining antibodies binding specifically to an epitope resulting from in vivo modification of a biomolecule or biomolecular complex, where the in vivo modification results from expression of a transgene in an animal. An example of such a biomolecule or biomolecular complex is LDL and an example of such a transgene is human myeloperoxidase. Resulting antibodies and methods of using the antibodies are also described.
    Type: Application
    Filed: August 16, 2012
    Publication date: June 5, 2014
    Inventor: Victor Manneh
  • Patent number: 8741298
    Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: June 3, 2014
    Assignee: Neotope Biosciences Limited
    Inventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
  • Patent number: 8728740
    Abstract: Epitopes localized on FNIII-8 repeat that are normally cryptic but are unmasked by insertion of FNIII-B into the FN molecule and are recognized by specific ligands are described; antibodies or their fragments able to identify the above said epitope are also described.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: May 20, 2014
    Assignee: Sirius-Biotech S.R.L.
    Inventors: Patrizia Castellani, Francesca Sassi, M. Barbara Carnemolla, Laura Borsi, Enrica Balza
  • Patent number: 8729240
    Abstract: Provided is a monoclonal antibody against slightly oxidized LDL, which can play a role as an important tool in the research and development of oxidized LDL. Also provided are a kit for the simple detection of slightly oxidized LDL and a method for the simple detection of slightly oxidized LDL from the biological sample of a subject to be tested which use the monoclonal antibody. By means of ELISA (Enzyme-Linked Immunosorbent Assay) using the monoclonal antibody as the solid phase antibody and an anti-apolipoprotein B antibody as the detection antibody, the degree of reaction between a severely oxidized low-density lipoprotein and the monoclonal antibody is low in comparison to the degree of reaction between a slightly oxidized low-density lipoprotein and the monoclonal antibody, and the monoclonal antibody specifically reacts with an oxidized low-density lipoprotein.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: May 20, 2014
    Assignee: National University Corporation Hokkaido University
    Inventors: Hitoshi Chiba, Seiichi Kobayashi, Hiroyuki Furukawa
  • Patent number: 8716031
    Abstract: Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: May 6, 2014
    Assignees: RIKEN, Animal Allergy Clinical Laboratories
    Inventors: Kenichi Masuda, Yasuyuki Ishii, Nobutaka Yasuda
  • Patent number: 8715672
    Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: May 6, 2014
    Assignee: CSL Behring GmbH
    Inventors: Bernhard Nieswandt, Thomas Renne
  • Publication number: 20140112932
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Application
    Filed: August 23, 2013
    Publication date: April 24, 2014
    Applicants: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
  • Patent number: 8703140
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: April 22, 2014
    Assignees: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: V. Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Gilkeson
  • Patent number: 8679496
    Abstract: The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: March 25, 2014
    Assignee: Glaxo Group Limited
    Inventors: Edward Coulstock, Elena De Angelis, Haiqun Liu, Oliver Schon
  • Patent number: 8679503
    Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: March 25, 2014
    Assignee: Yale University
    Inventors: Jack A. Elias, Zhou Zhu
  • Patent number: 8652475
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: February 18, 2014
    Assignees: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: Vernon Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson
  • Patent number: 8652471
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 18, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Patent number: 8618263
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: December 31, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Jes Thorn Clausen
  • Patent number: 8613924
    Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the anti-bodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: December 24, 2013
    Assignee: Immunas Pharma, Inc.
    Inventors: Tatsuki Yokoseki, Yasuhide Okamoto, Makoto Umeda, Naofumi Takamatsu, Toshiyuki Ito, Yukiho Imai, Shinobu Fujii